BPC-157
Also known as: Body Protection Compound-157, Pentadecapeptide
BPC-157 is a synthetic gastric pentadecapeptide studied mainly in preclinical wound and gastrointestinal injury models. The proposed mechanism is tissue-protective and angiogenic: modulation of nitric oxide signaling, endothelial repair, collagen organization, and local inflammatory response rather than a classic receptor-targeted drug effect.
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Frontiers in pharmacology · 2021 · PMID 34267654
Split AM/PM for stable blood levels. Oral dose higher (500-1000 mcg/day) for gut-specific use.
Mild injury 2-4wk, severe/post-surgical 4-6wk, GI 4-6wk, chronic 6-8wk. No loading/tapering required. No PCT required.
Injectable superior for soft tissue; oral effective for gut
Contraindications
- • Cancer/tumor history (VEGF/angiogenesis concern)
- • Autoimmune disorders (variable immune modulation)
Common side effects
- • Nausea
- • Lightheadedness
- • Headache (when stacking with GH secretagogues)
- • Dizziness (vasodilation)
- • Injection site irritation
Serious risks
- • Tumor growth acceleration in cancer patients (theoretical)
Drug interactions
- • Avoid NSAIDs during use
Pregnancy / breastfeeding
No data — consult clinician
- Cycle length varies wildly in published protocols (2-12 weeks) — no consensus
- Oral capsules have questionable efficacy vs injectable/oral liquid
- Wide therapeutic window does not mean zero risk
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.